title: Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids.
abstract: OBJECTIVE
  Rifampicin has been used for the treatment of patients with jaundice and pruritus. This study evaluated the effect of rifampicin on the expression of different detoxification systems and bile acid transporters during in-vivo and in-vitro experimental models of cholestasis.
  
  
  METHODS
  Rifampicin was administered to glycochenodeoxycholic acid (GCDCA)-treated human hepatocytes and bile duct-obstructed rats. Different parameters related to cell death, and the expression of phase I and II drug metabolizing enzymes (DME) and bile acid transporters were determined.
  
  
  RESULTS
  The induction of hepatocellular injury induced by cholestasis was associated with a reduction in cytochrome P4503A4 (CYP3A4), CYP7A1, and UDP-glucuronosyltransferase 2B4 (UGT2B4) expression, as well as an increase in import (Na(+)-taurocholate co-transporting polypeptide, NTCP) system expression. The beneficial properties of rifampicin were associated with an increase in DME and export bile acid systems (multidrug resistance-associated protein 4, MRP4, and bile acid export pump to bile duct, BSEP) expression, as well as a reduction in NTCP expression.
  
  
  CONCLUSIONS
  The beneficial effect of rifampicin in cholestasis is associated with an increase in DME expression involved in toxic, bile acid and cholesterol metabolism, as well as a reduction in the bile acid importing system in hepatocytes.
authors.affiliation: Liver Research Unit, Hospital Universitario Reina Sofía, IMIBIC (Instituto Maimónides para la Investigación Biomédica de Córdoba), Av. Menéndez Pidal s/n, 14004 Córdoba, Spain.
authors.forename: Raúl
authors.initials: R
authors.lastname: González
authors.forename: Adolfo
authors.initials: A
authors.lastname: Cruz
authors.forename: Gustavo
authors.initials: G
authors.lastname: Ferrín
authors.forename: Pedro
authors.initials: P
authors.lastname: López-Cillero
authors.forename: Javier
authors.initials: J
authors.lastname: Briceño
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Gómez
authors.forename: Sebastián
authors.initials: S
authors.lastname: Rufián
authors.forename: Javier
authors.initials: J
authors.lastname: Padillo
authors.forename: Manuel
authors.initials: M
authors.lastname: De la Mata
authors.forename: Jose J G
authors.initials: JJ
authors.lastname: Marin
authors.forename: Jordi
authors.initials: J
authors.lastname: Muntané
mesh_terms: D000818:Animals; D017209:Apoptosis; D001647:Bile Acids and Salts / Q000378:metabolism; D002352:Carrier Proteins / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics*; D002478:Cells, Cultured; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D002779:Cholestasis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D005786:Gene Expression Regulation; D005999:Glycochenodeoxycholic Acid / Q000633:toxicity; D006498:Hepatectomy; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics*; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012293:Rifampin / Q000494:pharmacology*
chemical_list: D001647:Bile Acids and Salts; D002352:Carrier Proteins; D004791:Enzyme Inhibitors; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; C037643:bile acid binding proteins; D005999:Glycochenodeoxycholic Acid; D012293:Rifampin